{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:41:41Z","timestamp":1791247301623,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["OFLCG22may-0011"],"award-info":[{"award-number":["OFLCG22may-0011"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tips.2025.07.014","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:35:40Z","timestamp":1755668140000},"page":"325-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy"],"prefix":"10.1016","volume":"47","author":[{"given":"Mengying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Ting","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-2764","authenticated-orcid":false,"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.07.014_bb0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2025.07.014_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.tips.2025.07.014_bb0015","first-page":"1098","article-title":"Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy","volume":"13","author":"Bahr","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.tips.2025.07.014_bb0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S513141","article-title":"From monotherapy to combination strategies: redefining treatment approaches for multiple-cause macular edema","volume":"19","author":"Zhu","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.tips.2025.07.014_bb0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0035","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tips.2025.07.014_bb0045","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2025.07.014_bb0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis","volume":"2","author":"Tuttle","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.tips.2025.07.014_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.963615","article-title":"The pathophysiological mechanisms underlying diabetic retinopathy","volume":"10","author":"Wei","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tips.2025.07.014_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2025.07.014_bb0065","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2165\/11208090-000000000-00000","article-title":"Fenofibrate: a review of its use in dyslipidaemia","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2025.07.014_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0075","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.2337\/db06-1206","article-title":"n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner","volume":"56","author":"Neschen","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0080","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/612089","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"2010","author":"Rakhshandehroo","year":"2010","journal-title":"PPAR Res."},{"key":"10.1016\/j.tips.2025.07.014_bb0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.17305\/bb.2022.8534","article-title":"Anti-inflammatory role of fenofibrate in treating diseases","volume":"23","author":"Jin","year":"2023","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.tips.2025.07.014_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/13510002.2023.2272386","article-title":"Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies","volume":"28","author":"Gao","year":"2023","journal-title":"Redox Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00109-007-0257-3","article-title":"Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose","volume":"86","author":"Zanetti","year":"2008","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.tips.2025.07.014_bb0100","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00018-003-2322-6","article-title":"Fenofibrate inhibits angiogenesis in vitro and in vivo","volume":"60","author":"Varet","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2025.07.014_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.580884","article-title":"Fenofibrate inhibits subretinal fibrosis through suppressing TGF-\u03b2-Smad2\/3 signaling and Wnt signaling in neovascular age-related macular degeneration","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.07.014_bb0110","article-title":"Correlation between diabetic retinopathy and diabetic nephropathy: a two-sample Mendelian randomization study","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tips.2025.07.014_bb0115","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4103\/ijo.IJO_1237_21","article-title":"Clinical correlation of diabetic retinopathy with nephropathy and neuropathy","volume":"69","author":"Saini","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.tips.2025.07.014_bb0120","article-title":"The relationship between diabetic retinopathy and diabetic nephropathy in type 2 diabetes","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tips.2025.07.014_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.tips.2025.07.014_bb0130","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2025.07.014_bb0135","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DDDT.S405266","article-title":"Fenofibrate attenuates renal tubular cell apoptosis by up-regulating MCAD in diabetic kidney disease","volume":"17","author":"Tang","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.tips.2025.07.014_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076836","article-title":"Fenofibrate attenuated glucose-induced mesangial cells proliferation and extracellular matrix synthesis via PI3K\/AKT and ERK1\/2","volume":"8","author":"Zeng","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2025.07.014_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0150","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.freeradbiomed.2020.10.323","article-title":"Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy","volume":"162","author":"Li","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208399","article-title":"Neuroprotective effects of PPAR\u03b1 in retinopathy of type 1 diabetes","volume":"14","author":"Pearsall","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2025.07.014_bb0160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/jcm10010126","article-title":"Fenofibrate reduces the severity of neuroretinopathy in a type 2 model of diabetes without inducing peroxisome proliferator-activated receptor alpha-dependent retinal gene expression","volume":"10","author":"Enright","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0165","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/02713683.2018.1501072","article-title":"Fenofibrate ameliorates oxidative stress-induced retinal microvascular dysfunction in diabetic rats","volume":"43","author":"Li","year":"2018","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.tips.2025.07.014_bb0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11892-016-0786-7","article-title":"Fenofibrate and diabetic retinopathy","volume":"16","author":"Knickelbein","year":"2016","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.tips.2025.07.014_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.51789\/cmsj.2022.2.e13","article-title":"Exploring fenofibrate formulations for the treatment of lipid disorders: past, present, and future","volume":"2","author":"Nguyen","year":"2022","journal-title":"Cardiometab. Syndr. J."},{"key":"10.1016\/j.tips.2025.07.014_bb0185","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2025.07.014_bb0190","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.tips.2025.07.014_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/dc09-0621","article-title":"Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy","volume":"33","author":"Forsblom","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2025.07.014_bb0200","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0205","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2025.07.014_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111612","article-title":"Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes","volume":"210","author":"Jenkins","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tips.2025.07.014_bb0215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ekir.2018.09.006","article-title":"Associations of fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes","volume":"4","author":"Frazier","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0220","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of fenofibrate on progression of diabetic retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid."},{"key":"10.1016\/j.tips.2025.07.014_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089518","article-title":"Randomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE study): study protocol for a randomised control trial","volume":"14","author":"Nguyen","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.tips.2025.07.014_bb0230","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00125-021-05532-1","article-title":"Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial","volume":"64","author":"Bonora","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2025.07.014_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202200106","article-title":"Optimised plasma sample preparation and LC-MS analysis to support large-scale proteomic analysis of clinical trial specimens: application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial","volume":"17","author":"O'Rourke","year":"2023","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.tips.2025.07.014_bb0240","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2002-01-0185","article-title":"Kallistatin is a new inhibitor of angiogenesis and tumor growth","volume":"100","author":"Miao","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.07.014_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108617","article-title":"The role of peroxisome proliferator-activated receptors in healthy and diseased eyes","volume":"208","author":"Escandon","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.tips.2025.07.014_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.788663","article-title":"Peroxisome proliferator-activated receptor \u03b1 activation protects retinal ganglion cells in ischemia\u2013reperfusion retinas","volume":"8","author":"Yao","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910485","article-title":"Translational research and therapies for neuroprotection and regeneration of the optic nerve and retina: a narrative review","volume":"25","author":"Oshitari","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.07.014_bb0260","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2337\/db19-0898","article-title":"Pathogenic role of PPAR\u03b1 downregulation in corneal nerve degeneration and impaired corneal sensitivity in diabetes","volume":"69","author":"Matlock","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64451-4","article-title":"Topical and oral peroxisome proliferator-activated receptor-\u03b1 agonist ameliorates diabetic corneal neuropathy","volume":"14","author":"Mansoor","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0270","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/ph14030223","article-title":"Fenofibrate protects against retinal dysfunction in a murine model of common carotid artery occlusion-induced ocular ischemia","volume":"14","author":"Lee","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tips.2025.07.014_bb0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2337\/db11-0413","article-title":"Therapeutic effects of PPAR\u03b1 agonists on diabetic retinopathy in type 1 diabetes models","volume":"62","author":"Chen","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0280","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2337\/db16-1246","article-title":"Pathogenic role of microRNA-21 in diabetic retinopathy through downregulation of PPAR\u03b1","volume":"66","author":"Chen","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0285","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1166\/nnl.2020.3207","article-title":"Fenofibrate improves the progression of diabetic retinopathy by regulating miR-21-IL6R Axis","volume":"12","author":"Zhang","year":"2020","journal-title":"Nanosci. Nanotechnol. Lett."},{"key":"10.1016\/j.tips.2025.07.014_bb0290","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2337\/db22-0654","article-title":"Regulation of monocyte activation by PPAR\u03b1 through interaction with the cGAS-STING pathway","volume":"72","author":"Dong","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0295","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/antiox9080712","article-title":"Protective effect of fenofibrate on oxidative stress-induced apoptosis in retinal\u2013choroidal vascular endothelial cells: implication for diabetic retinopathy treatment","volume":"9","author":"Hsu","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.tips.2025.07.014_bb0300","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00441-018-2974-z","article-title":"Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt\/\u03b2-catenin pathway activation","volume":"376","author":"Liu","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.tips.2025.07.014_bb0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41514-020-00050-7","article-title":"Fenofibrate prevents iron induced activation of canonical Wnt\/\u03b2-catenin and oxidative stress signaling in the retina","volume":"6","author":"Mandala","year":"2020","journal-title":"NPJ Aging Mech. Dis."},{"key":"10.1016\/j.tips.2025.07.014_bb0310","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1089\/jop.2020.0068","article-title":"Effects of modified low-density lipoproteins and fenofibrate on an outer blood-retina barrier model: implications for diabetic retinopathy","volume":"36","author":"Fu","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2025.07.014_bb0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ebiom.2016.09.025","article-title":"Fenofibrate inhibits cytochrome P450 epoxygenase 2C activity to suppress pathological ocular angiogenesis","volume":"13","author":"Gong","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tips.2025.07.014_bb0320","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1167\/iovs.18-24155","article-title":"Fenofibrate exerts protective effects in diabetic retinopathy via inhibition of the ANGPTL3 pathway","volume":"59","author":"Wang","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tips.2025.07.014_bb0325","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00592-020-01565-x","article-title":"Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier","volume":"57","author":"Mazzeo","year":"2020","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.tips.2025.07.014_bb0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.51329\/mehdiophthal1492","article-title":"Fenofibrate and diabetic retinopathy","volume":"13","author":"Karti","year":"2024","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"10.1016\/j.tips.2025.07.014_bb0335","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.2337\/db13-0800","article-title":"An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes","volume":"62","author":"Noonan","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0340","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00125-022-05655-z","article-title":"Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies","volume":"65","author":"Jenkins","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2025.07.014_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41433-024-03410-9","article-title":"Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial","volume":"39","author":"Varughese","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.tips.2025.07.014_bb0350","article-title":"Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1\u03b1 in db\/db mice","volume":"9","author":"Hong","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2025.07.014_bb0355","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/ki.2010.530","article-title":"Fenofibrate, a PPAR\u03b1 agonist, has renoprotective effects in mice by enhancing renal lipolysis","volume":"79","author":"Tanaka","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2025.07.014_bb0360","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00011-006-6190-z","article-title":"Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats","volume":"57","author":"Chen","year":"2008","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.tips.2025.07.014_bb0365","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1258\/ebm.2009.009218","article-title":"Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-\u03baB and transforming growth factor-\u03b21\/Smad3 in diabetic nephropathy","volume":"235","author":"Li","year":"2010","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0370","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1002\/jcb.27055","article-title":"Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy","volume":"119","author":"Yaribeygi","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tips.2025.07.014_bb0375","doi-asserted-by":"crossref","first-page":"F618","DOI":"10.1152\/ajprenal.00309.2013","article-title":"Proximal tubule PPAR\u03b1 attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction","volume":"305","author":"Li","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.tips.2025.07.014_bb0380","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/13813455.2016.1164186","article-title":"Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-\u03b21\/Smad3 signaling pathway","volume":"122","author":"Al-Rasheed","year":"2016","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.tips.2025.07.014_bb0385","first-page":"10653","article-title":"Fenofibrate, a PPAR\u03b1 agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB","volume":"8","author":"Zuo","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.tips.2025.07.014_bb0390","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.freeradbiomed.2016.02.002","article-title":"Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy","volume":"93","author":"Cheng","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0395","doi-asserted-by":"crossref","first-page":"553","DOI":"10.7150\/ijbs.40643","article-title":"The role of Akt2 in the protective effect of fenofibrate against diabetic nephropathy","volume":"16","author":"Cheng","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tips.2025.07.014_bb0400","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000381190","article-title":"Renoprotective effects of fenofibrate via modulation of LKB1\/AMPK mRNA expression and endothelial dysfunction in a rat model of diabetic nephropathy","volume":"95","author":"Al-Rasheed","year":"2015","journal-title":"Pharmacology"},{"key":"10.1016\/j.tips.2025.07.014_bb0405","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.redox.2018.09.024","article-title":"Fenofibrate improves vascular endothelial function and contractility in diabetic mice","volume":"20","author":"Xu","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.tips.2025.07.014_bb0410","article-title":"PPAR-\u03b1 agonist fenofibrate prevented diabetic nephropathy by inhibiting M1 macrophages via improving endothelial cell function in db\/db mice","volume":"8","author":"Feng","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.tips.2025.07.014_bb0415","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/cells13171446","article-title":"PPAR-\u03b1 insufficiency enhances doxorubicin-induced nephropathy in PPAR-\u03b1 knockout mice and a murine podocyte cell line","volume":"13","author":"Matsuta","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.tips.2025.07.014_bb0420","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/ki.2011.17","article-title":"Peroxisome proliferator-activated receptor-\u03b1 is renoprotective in doxorubicin-induced glomerular injury","volume":"79","author":"Zhou","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2025.07.014_bb0425","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2019.04.039","article-title":"Group 1 innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor \u03b1","volume":"96","author":"Okabayashi","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2025.07.014_bb0430","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11033-020-06032-y","article-title":"Pemafibrate prevents retinal neuronal cell death in NMDA-induced excitotoxicity via inhibition of p-c-Jun expression","volume":"48","author":"Fujita","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0435","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/bioengineering11121247","article-title":"Pemafibrate induces a low level of PPAR\u03b1 agonist-stimulated mRNA expression of ANGPTL4 in ARPE19 cell","volume":"11","author":"Ohguro","year":"2024","journal-title":"Bioengineering"},{"key":"10.1016\/j.tips.2025.07.014_bb0440","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.3390\/ijms21176243","article-title":"Pemafibrate protects against retinal dysfunction in a murine model of diabetic retinopathy","volume":"21","author":"Tomita","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.07.014_bb0445","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4093\/dmj.2023.0370","article-title":"Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease","volume":"48","author":"Izumihara","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.tips.2025.07.014_bb0450","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00024677-200504050-00004","article-title":"A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?","volume":"4","author":"Steiner","year":"2005","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.tips.2025.07.014_bb0455","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ki.2011.254","article-title":"The peroxisome proliferator-activated receptor-\u03b1 agonist, BAY PP1, attenuates renal fibrosis in rats","volume":"80","author":"Boor","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2025.07.014_bb0460","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3390\/pharmaceutics14020384","article-title":"Fenofibrate nano-eyedrops ameliorate retinal blood flow dysregulation and neurovascular coupling in type 2 diabetic mice","volume":"14","author":"Hanaguri","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tips.2025.07.014_bb0465","first-page":"1328","article-title":"Therapeutic effects of fenofibrate nano-emulsion eye drops on retinal vascular leakage and neovascularization","volume":"10","author":"Huang","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.tips.2025.07.014_bb0470","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.3390\/molecules27154755","article-title":"Development of fenofibrate\/randomly methylated \u03b2-cyclodextrin-loaded Eudragit(\u00ae) RL 100 nanoparticles for ocular delivery","volume":"27","author":"Khin","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2025.07.014_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125417","article-title":"Delivery of fenofibrate to ocular tissues using 2-hydroxypropyl-\u03b2-cyclodextrin-based micelles","volume":"673","author":"Klahan","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.tips.2025.07.014_bb0480","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.18240\/ijo.2022.12.16","article-title":"Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice","volume":"15","author":"Ngah","year":"2022","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.tips.2025.07.014_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101428","article-title":"Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: a propensity-matched cohort study","volume":"49","author":"Kim","year":"2023","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tips.2025.07.014_bb0490","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/dom.15295","article-title":"The effect of empagliflozin and fenofibrate therapies, alone and in combination, on the serum urate concentration in hyperuricaemic type 2 diabetes","volume":"26","author":"Davis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tips.2025.07.014_bb0495","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2010.03.002","article-title":"The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy","volume":"636","author":"Arora","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.07.014_bb0500","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927647","article-title":"Fenofibrate and impaired taste perception in type 2 diabetes","volume":"21","author":"Davis","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0505","article-title":"Fenofibrate: a nonlithogenic means of recurrent drug-induced pancreatitis","volume":"2018","author":"Kassim","year":"2018","journal-title":"Case Rep. Gastrointest. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087179","article-title":"Uridine prevents fenofibrate-induced fatty liver","volume":"9","author":"Le","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2025.07.014_bb0515","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaophthalmol.2022.0633","article-title":"Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy","volume":"140","author":"Meer","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.tips.2025.07.014_bb0520","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2215\/CJN.06200518","article-title":"Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes","volume":"13","author":"Mottl","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tips.2025.07.014_bb0525","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/cr1333","article-title":"A significant increase of estimated glomerular filtration rate after switching from fenofibrate to pemafibrate in type 2 diabetic patients","volume":"12","author":"Yanai","year":"2021","journal-title":"Cardiol. Res."},{"key":"10.1016\/j.tips.2025.07.014_bb0530","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11883-009-0051-5","article-title":"Fibrate therapy and renal function","volume":"11","author":"Sica","year":"2009","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.tips.2025.07.014_bb0535","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0540","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12944-020-01254-2","article-title":"Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia","volume":"19","author":"Sun","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.tips.2025.07.014_bb0545","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1248\/yakushi.20-00259","article-title":"Effects of fibrates on risk of development of diabetic retinopathy in Japanese working age patients with type 2 diabetes and dyslipidemia: a retrospective cohort study","volume":"141","author":"Akimoto","year":"2021","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.tips.2025.07.014_bb0550","article-title":"Design, recruitment and baseline characteristics of the LENS trial","volume":"41","year":"2024","journal-title":"Diabet. Med."},{"key":"10.1016\/j.tips.2025.07.014_bb0555","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/HJH.0b013e32832dd5c4","article-title":"Angiopoietins in arterial hypertension: a mechanism of adaptation or a target for treatment?","volume":"27","author":"Shantsila","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.tips.2025.07.014_bb0560","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/db19-0973","article-title":"PPARA polymorphism influences the cardiovascular benefit of fenofibrate in type 2 diabetes: findings from ACCORD-Lipid","volume":"69","author":"Morieri","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.07.014_bb0565","doi-asserted-by":"crossref","first-page":"F397","DOI":"10.1152\/ajprenal.00124.2024","article-title":"Aberrant proximal tubule DNA methylation underlies phenotypic changes related to kidney dysfunction in patients with diabetes","volume":"327","author":"Marumo","year":"2024","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.tips.2025.07.014_bb0570","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00125-023-05997-2","article-title":"Racial\/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the accord trial","volume":"66","author":"Cromer","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2025.07.014_bb0575","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3803\/EnM.2024.1995","volume":"39","author":"Kim","year":"2024","journal-title":"Endocrinol. Metab."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:51:39Z","timestamp":1772873499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725001579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0165614725001579"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.07.014","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}